Elevation Oncology reports Q1 EPS (24c), consensus (18c)

Estimates that it will have cash, cash equivalents and marketable securities of $30M-$35M as of June 30, 2025, which is expected to fund its current operations into the second half of 2026. “We recently presented preclinical proof-of-concept data for EO-1022, reaffirming its potential as a differentiated HER3 ADC, and supporting our goal of providing a safer and more effective option for patients with HER3-expressing solid tumors,” said CEO Joseph Ferra. “In parallel, we are engaged in efforts to explore a range of strategic alternatives, with the objective of identifying and capitalizing on the opportunity that is in the best interest of our shareholders. We look forward to providing an update at the appropriate time.”